FDA OKs Turing Medical’s Precision Brain Mapping for Neuromodulation

Turing Medical, a company focused on precision brain mapping and targeting technologies, has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its Bullsai Identify platform.
 
Bullsai Identify is an automated, end-to-end platform and mapping solution that generates personalized, precise data to facilitate planning for neuromodulation therapies for neurological disorders like Parkinson’s disease and essential tremor.
 
The tool’s advanced imaging and algorithms create detailed, patient-specific brain maps. That way, physicians can more accurately identify the best targets for deep brain stimulation (DBS) and focused ultrasound (FUS). Using personalized data, Bullsai Identify hopes to improve therapy outcomes, reduce off-target effects, and shorten recovery times.
 
This week, Turing Medical launched Bullsai Identify at the World Society of Stereotactic and Functional Neurosurgery (WSSFN) conference. The company said it’s collaborating with leading hospitals, teaching institutions, and clinics to introduce this technology and gather valuable insights for future product development.
 
“We are thrilled about the FDA clearance of Bullsai Identify, as it represents a major advancement for both Turing Medical and the field of neuromodulation,” said Ken Bruener, president and CEO of Turing Medical. “Our automated platform can optimize treatment planning and help establish a new standard of care for neurological conditions.”
 
“Bullsai Identify’s ability to provide detailed, patient-specific insights will help clinicians make more informed decisions, ultimately improving quality of life for those affected by neurodegenerative and neuropsychiatric disorders as well,” added Dr. Damien Fair, co-founder of Turing Medical.